Invanz

Ertapenem, the active ingredient in Invanz, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It provides broad‑spectrum bactericidal activity against Gram‑negative and Gram‑positive organisms and is employed to treat serious infections in adult patients.

GNH USA supplies Invanz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide with reliable cold‑chain logistics and regulatory support. The company adheres to stringent quality standards and provides comprehensive documentation for import and distribution across multiple regions.

Invanz (ertapenem) is used to treat infections caused by susceptible bacteria in several clinical categories.

- Complicated intra‑abdominal infections: achieves bacterial eradication in severe intra‑abdominal infections following surgery or perforation. - Complicated skin and soft tissue infections: provides effective therapy for deep tissue infections such as cellulitis or necrotizing fasciitis. - Community‑acquired pneumonia: delivers bactericidal activity against common respiratory pathogens in adult patients. - Complicated urinary tract infections: resolves infections of the kidney and bladder caused by resistant organisms. - Diabetic foot infection: helps clear polymicrobial infections in diabetic foot ulcers.

Ertapenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Infusion site reactions (pain, erythema)

Serious or Rare Side Effects: - Seizures, especially in patients with CNS disorders - Severe allergic reactions such as anaphylaxis - Clostridioides difficile‑associated colitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When using Invanz, several precautionary measures should be observed to ensure safe and effective therapy. - Renal function assessment: evaluate creatinine clearance before initiating therapy and adjust dose in renal impairment. - Hypersensitivity monitoring: watch for signs of allergic reaction such as rash, pruritus or anaphylaxis. - Seizure risk: avoid use in patients with a history of seizures or CNS disorders unless benefits outweigh risks. - Valproic acid interaction: discontinue or replace valproic acid, as ertapenem can reduce its plasma concentrations. - Concomitant nephrotoxic agents: monitor renal parameters when used with other nephrotoxic drugs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ertapenem can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: co‑administration markedly reduces valproate levels, risking loss of seizure control. - Other carbapenems: combined use may increase toxicity without added benefit. - Live bacterial vaccines: reduced immunogenic response, avoid vaccination during therapy.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): monitor INR for possible changes. - Oral contraceptives: efficacy may be decreased, consider alternative contraception. - Diuretics: monitor electrolytes and renal function due to potential additive nephrotoxicity.